Improved clinical outcome of paediatric bone marrow recipients using a test and Bayesian pharmacokinetic individualization of busulfan dosage regimens

Bone Marrow Transplantation

Volumn 28, Issue 8, 2001, Pages 743-751

  Bleyzac, N ^a,b   Souillet, G ^a   Magron, P ^a   Janoly, A ^a   Martin, P ^a,b   Bertrand, Y ^a   Galambrun, C ^a   Dai, Q ^a   Maire, P ^b,c   Jelliffe, R W ^c   Aulagner, G ^a  

^a HÔPITAL DEBROUSSE   (France)

^b A Charial Hospital   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bayesian pharmacokinetic monitoring; BMT; Busulfan; Paediatrics

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HEPARIN; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; PROSTAGLANDIN E1; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BONE MARROW TRANSPLANTATION; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIQUID CHROMATOGRAPHY; MALE; MORTALITY; OUTCOMES RESEARCH; PARAMETER; PREDICTION; PRIORITY JOURNAL; RECIPIENT; RELAPSE; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL; TOXICITY; VEIN OCCLUSION;

ADOLESCENT; ALKYLATING AGENTS; AREA UNDER CURVE; BAYES THEOREM; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; GENETIC DISEASES, INBORN; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; INFANT; LIFE TABLES; MALE; MELPHALAN; PROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035179652     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703207     Document Type: Article

References (30)

1. Busulfan and total body irradiation as anti-haemopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation
2. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis
3. Antithrombine III for the treatment of chemotherapy induced organ dysfunction following bone marrow transplantation
4. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide versus total body irradiation: A meta-analysis
5. Ursodiol to prevent hepatic veno-occlusive disease
6. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia
7. Veno-occlusive disease of the liver complicating bone marrow transplantation
8. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
9. Association of busulfan fan area under the curve with veno-occlusive disease following BMT
10. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
11. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children
12. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
13. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
14. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
15. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
16. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan
17. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
18. Individualizing drug dosage regimens: Roles of population and pharmacodynamic models, bayesian fitting, and adaptive control
19. Rapid and sensitive high-performace liquid chromatographic method for busulfan assay in plasma
20. Optimal sampling times for pharmacokinetic experiments
21. Robust design for the estimation on hyperparameters in population pharmacokinetics
22. Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration and continuous hemodialysis
23. Amplification of human minisatellites by the PCR: Toward fingerprinting of single cells
24. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia
25. Busulphan level and early mortality in thalassemia patients after BMT
26. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease
27. Control of intra- and inter-patient variability by Bayesian forecasting of busulfan dosage regimens in pediatric BMT
28. IVIG prophylaxis in allogeneic sibling SCT: Preliminary results of a randomized dose-effect, placebo-controlled, double-blind, multicenter trial
29. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: A prospective study